Clinical Trials
114 trialsLiposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
University Hospital, Linkoeping
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
HIPEC
Wake Forest University Health Sciences
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
M.D. Anderson Cancer Center
INSPIRE
University Health Network, Toronto
ACROPOLI
SOLTI Breast Cancer Research Group
CRS/HIPEC
Mercy Medical Center
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
University Medical Center Groningen
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Loyola University
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ludwig Institute for Cancer Research
M10MKO
The Netherlands Cancer Institute
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Shandong University
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
BOLD
ARCAGY/ GINECO GROUP
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
t
Peking Union Medical College Hospital
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
TIVO
Northwestern University
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Peking University Third Hospital
CHIMOVIP
Groupe Hospitalier Diaconesses Croix Saint-Simon
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
CLIO
Universitaire Ziekenhuizen KU Leuven
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Chang Gung Memorial Hospital
Cell-free DNA Methylation for Epithelial Ovarian Cancer
Peking Union Medical College Hospital
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
AVANIRA3
Jiangsu Cancer Institute & Hospital
ANLOLA
Jiangsu Cancer Institute & Hospital
68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
Peking Union Medical College Hospital
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
First Affiliated Hospital of Harbin Medical University
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
Jonsson Comprehensive Cancer Center
HIPEC
Krankenhaus Barmherzige Schwestern Linz
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
University of Maryland, Baltimore
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center